Hologic, Inc (HOLX) concluded trading on Thursday at a closing price of $65.45, with 8.16 million shares of worth about $533.8 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -20.62% during that period and on February 06, 2025 the price saw a loss of about -10.10%. Currently the company’s common shares owned by public are about 225.72M shares, out of which, 222.47M shares are available for trading.
Stock saw a price change of -9.31% in past 5 days and over the past one month there was a price change of -11.28%. Year-to-date (YTD), HOLX shares are showing a performance of -9.21% which decreased to -9.15% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $68.61 but also hit the highest price of $84.67 during that period. The average intraday trading volume for Hologic, Inc shares is 2.18 million. The stock is currently trading -7.72% below its 20-day simple moving average (SMA20), while that difference is down -10.62% for SMA50 and it goes to -15.00% lower than SMA200.
Hologic, Inc (NASDAQ: HOLX) currently have 225.72M outstanding shares and institutions hold larger chunk of about 104.77% of that.
The stock has a current market capitalization of $14.77B and its 3Y-monthly beta is at 0.96. PE ratio of stock for trailing 12 months is 20.68, while it has posted earnings per share of $3.16 in the same period. Its PEG reads 2.65 and has Quick Ratio of 2.78 while making debt-to-equity ratio of 0.53. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HOLX, volatility over the week remained 2.64% while standing at 2.25% over the month.
Stock’s fiscal year EPS is expected to rise by 4.59% while it is estimated to increase by 9.07% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on Feb-07-25 offering a Market perform rating for the stock and assigned a target price range of between $80 and $75 to it. On December 13, 2024, Wolfe Research Initiated their recommendations, while on December 10, 2024, Needham Reiterated their ratings for the stock with a price target of $90. Stock get a Hold rating from Jefferies on December 10, 2024.
